Pulmonary Arterial Hypertension
Lucie Clapp is a Professor of Vascular Physiology with UCL, an editor for the British Journal of Pharmacology, and peer reviews for numerous journals and also grant awarding bodies. Her research concerns elucidating the biophysical and functional properties of vascular potassium channels, with a strong emphasis on their roles in sepsis, vascular remodelling and pulmonary hypertension. Work has specifically focused on in vitro and in vivo models of septic shock in rodents and humans, the biochemistry and confocal imaging of calcineurin and its role in mediating smooth muscle proliferation, and the mechanistic basis underlying the therapeutic effects of prostacyclins in pulmonary arterial hypertension (PAH). She was involved in the first clinical use of terlipressin in sepsis, the identification of a new clinical syndrome associated with drug-induced hyperkalemia and proof-of-concept of novel treatments for PAH.
She has held post-doctoral positions at The University of Massachusetts Medical School and St Thomas' Hospital, before being awarded a Wellcome Trust Career Development Fellowship. She then joined the UCL Centre for Clinical Pharmacology in 1996 as an MRC Senior Fellow in Basic Science, becoming a Reader in 2002 and then Professor of Vascular Physiology in 2005. She was elected Fellow of the Pulmonary Vascular Research Institute in 2010 and a Fellow of the Society of Biology in 2011. Additionally, she has productive relationships with several pharmaceutical companies, and regularly provides information to market research companies.
Visit Lucie Clapp's IRIS Profile >
Email address: firstname.lastname@example.org